Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semuloparin vs Enoxaparin for VTE Prevention in Acutely Ill Medical Patients
NCT00714597Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jul 2008
- Primary completion
- Mar 2009
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of semuloparin in venous thromboembolism (VTE), sponsored by Sanofi. Primary endpoint: Percentage of Participants Who Experienced Venous Thromboembolism Event (VTE) or VTE-related Death at 15 days. Started Jul 2008; status: terminated.
02
Drugs
semuloparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00714597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00714597.